Oric Pharmaceuticals

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Oric Pharmaceuticals 是一家在股票代码 ORIC (US) 下上市的公司。

涉及Oric Pharmaceuticals的并购和融资。

• Oric Pharmaceuticals 刚刚宣布为 85 筹款数百万美元。 (公布2023六月28号).

查看带有其 14 名主要高管的组织结构图

Oric Pharmaceuticals 搜索最多的简介

• Jacob Chacko, Chief Executive Officer and Director
• Angie You, Director
• Mardi Dier, Director

高管在Oric Pharmaceuticals变化

• Keith Lui已作为Senior Vice President of Commercial and Medical Affairs加入公司  (新闻发布的2024八月6号).

创建提醒
跟踪 Oric Pharmaceuticals 的高管变动

Oric Pharmaceuticals 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。

Popular M&A news in 药店

• Bain Capital 已收购 Mitsubishi Tanabe Pharma (公布2025二月12号).
• Crown Laboratories 已收购 Revance Therapeutics (公布2025二月9号).
• Revance Therapeutics has announced the acquisition of Revance Therapeutics  (公布2025一月14号).

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

Oric Pharmaceuticals 的最新新闻稿

• ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call | ORIC Pharmaceuticals, Inc.
• ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II | ORIC Pharmaceuticals, Inc.
• View more press releases Close

关于 Oric Pharmaceuticals 的社交媒体

• Oric Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Oric Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube